Ibrutinib appears useful in the setting of primary and secondary CNS lymphoma but there is little data on the optimal way to use it in such a rare disease, Australian clinicians have found. It will be a case of continuing to accumulate the data as the drug is used in this indication, according to findings ...
Ibrutinib shows promise in CNS lymphoma
By Mardi Chapman
10 Dec 2019